Share Name Share Symbol Market Type Share ISIN Share Description
Realm Thera. LSE:RLM London Ordinary Share GB00B3XBCR18 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 9.75p 9.50p 10.00p 9.75p 9.75p 9.75p 10,000 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.8 -7.8 -11.8 - 13.43

Realm Thera. Share Discussion Threads

Showing 26 to 47 of 50 messages
Chat Pages: 2  1
AIM:RLM - "Review underway after Atopic Dermatitis miss" RLM’s randomised, double-blind, placebo controlled, Phase II clinical trial, PR022 showed no difference from vehicle in the primary endpoint of percentage change in Eczema Area Severity Index (EASI) versus baseline. The Company is now analysing the data to interpret the top-line result, as well as the other data collected in the study. The conclusions of this review will be used to inform decision-making going forward, and this includes evaluating the implications of these data for RLM’s preclinical HOCl dermatology pipeline in Acne and Psoriasis – both of which had been making good progress. RLM indicates that it will also review the possibility of acquiring one or more new assets, although no specific detail is available. They expect to disclose the outcome of the review in September. Pending the outcome of the review, we are suspending our forecasts and valuation that we can update when the Group’s strategic direction becomes clearer in September. In the meantime, RLM has the benefit of significant cash on the balance sheet, an experienced Executive team, and substantial IP filed. Read the full note here ...
Looking at what support their cash pile can give the share price They have 116 m shares and at the end of June US23m. Cash burn in H1 was US10m, including the NASDAQ listing costs. I am assuming they have reduced R&D on acne/ psioriasis to the minimum until next month when they make their review. At the end of Sept cash/ cash equivalents I estimate will be Us20m approx or approx 13.5p per share. Of course in the extremely unlikely event that they were to liquidate the company this cash balance would go down to say 11p a share after the costs of liquidation offset by the sale of their IP. PS Went on to the Nasdaq webpage to see what RLM did there but said price unchanged at $0 and no trades so perhaps RLM not live on NASDAQ yet.
Nothing new in the conference call. Just said what they said in the RNS that the information given was hot off the press and that need to digest it and in September there will be an update with how they will proceed with PRO22/AD as well as the acne and psioriasis programme or indeed buying some of the other assets they are looking at. They do have US23m in cash/equivalents and will not have the repeat of the US 1.5 m spent on the NASDAQ listing which will be enough to take the acne and psioriasis programme a good way forward. Rather kicking myself for not asking him how the scientists say this AD result affects their view of how the acne and/or psioriasis results will work out. I need to decide what to do with the fat end that I have PS Not speaking at the conference this afternoon
Realm Therapeutics (RLM) News Out Just Now
Come back at sub 5p for the dead cat bounce. B1
I also substantially reduced my exposure this morning and indeed am surprised that the price had not fallen further. Am planning to listen to the conference call.
What a basket case this has become - what's that two failed trials now since flotation. They tried to play it down in the RNS but market not having it. My small position (now even smaller) has been chopped now
MALVERN, PA, 14 August, 2018 - Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today reports preliminary top-line data from its Phase 2 trial of PR022 in Atopic Dermatitis, as well as financial results for the six months ended 30 June, 2018. In a randomized, double-blind, vehicle controlled, Phase 2 clinical trial of 122 patients, PR022 showed no difference from vehicle in the primary endpoint of percent change in Eczema Area Severity Index (EASI) versus baseline. "PR022 did not show the desired effect in this trial," said Alex Martin, CEO of Realm Therapeutics. "Having just received the data, we are working to better understand this outcome and to analyze all of the data collected in the study. We are conducting a full review to determine whether there is a path forward for our proprietary technology in Atopic Dermatitis, and to evaluate the implications for our Acne and Psoriasis programs. We will provide an update on our plans in September. I would like to thank the patients and investigators who participated in this trial." CORPORATE AND FINANCIAL HIGHLIGHTS -- Cash, cash equivalents and short-term investments were $23.7 million as at 30 June 2018 (as at 31 December 2017: $33.9m). -- Investments in Research & Development (R&D) increased to $7.4 million (H1 2017: $3.0m) driven by additional investment in clinical development activities -- General and Administrative (G&A) expenses increased to $3.5 million (H1 2017: $1.6m) primarily due to Nasdaq listing costs. -- In July 2018, listed American Depositary Shares ("ADSs") representing the Company's ordinary shares on the Nasdaq Capital Market to facilitate the creation of a trading market in the US for the Company's securities and in satisfaction of obligations under a registration rights agreement entered into with investors who participated in the Company's October 2017 private placement. -- The US Patent and Trademark Office issued two new patents to Realm that expand the intellectual property portfolio around the Company's proprietary immunomodulatory technology in the treatment of inflammatory and autoimmune disorders.
Holy Moly I may buy some at 5p for a punt. :( Run my friends. Cash is low about £16m B1
Does anyone know what to make of this morning's RNS in which 22 is compared to an arthritis solution? Good to hear that top line readout still on track for September.
My eye caught this report on a Singapore company doing an AD Phase 1 with some interesting industry background.
as per name of thread : after today's encouraging news on enrollment completed for Phase II trial, updated ED research note just published. Freely accessible here:[ID]&d=%3D%3DANyQjM
New realm thread with charts and information
Disappointing and rather surprising news this morning and it will be interesting to see Martin's webcast presentation at the Cowen conference tomorrow. Had not expected abondonment so soon; of course 13 had less financial potential than 22 and what they said today that there is no crossover between 13 and 22 is that the prospects for 22 are unchanged with this news reflects my previous understanding. This will mean I assume that they will have finance to progress 22 that much further. I am assuming that 13 dry eye which is in preclinical is not affected; note no mention perhaps means that not regarded as important. One downer is that 13 was ahead of 22 so if things had gone without a hitch would have generated revenue sooner. Pleasantly surprised that there has been so much liquidity and have lightened up a bit.
Positive clinical and business update released today and new research note with valuation update now out from Equity Dev. Free access here: … AND you can see the CEO of Realm present at the next ED Private Investor Forum in London on Wed 28 March, register here:
The presentation given at the ProActive session in London and the earlier one in the US can be found here hxxp://
Realm Therapeutics will be presenting to investors at the upcoming Proactive One2One Forum on the evening of 25th January in London. For details and registration, please click here:
Equity Development have published a new clearly written note on RLM hxxps:// ED reckon RLM have cash till Q3 19; there are now 3 preclinical programmes and on one RLM023 we are told to expect in late 2018 a IND filing. On PR022 we should get a read out on the current Phase IIa in Q3 18 and on PR013’s phase IIb in Q2 18. They have a valuation of 110p per share which I take with a pinch of salt as it is still early days. So no hard news for 6 months +; given the lack of market activity-as far as I can see only 120k shares traded since November 22- we need to be prepared for the price to drift down given boredom.
The price fall of the last few days has come with little volume: Volume for the first three days of this week were 45k, 85k and 5k.
Thanks smraynot for setting up this new thread. Noted it made yesterdays's FT Small Cap Focus...which was inaccurate referring to a £16m marcap rather than a £50m one.
Wonderful webcast yesterday. With quality management and positive phase 11 trials this share could absolutely rocket. My short term target in excess of £5.
very surprised and very pleasantly so by the share price increase today
Chat Pages: 2  1
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180926 14:50:57